Bilateral pulmonary embolism while receiving tranexamic acid: a case report

[1] Bĕlohlávek J(2013)Pulmonary embolism, part I: epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism Exp Clin Cardiol 18 129-138

[2] Dytrych V(2018)Epidemiology, pathophysiology, and natural history of pulmonary embolism Semin Intervent Radiol 35 92-98

[3] Linhart A(2020)Advances in the diagnosis of acute pulmonary embolism F1000Res 9 F1000 Faculty Rev-44-316

[4] Turetz M(2017)Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis Wien Klin Wochenschr 129 303-37

[5] Sideris AT(2015)Uses of tranexamic acid Cont Educ Anaesth Crit Care Pain 15 32-97

[6] Friedman OA(2009)The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database BJOG 116 91-79

[7] Triphathi N(2018)Tranexamic acid therapy for postoperative bleeding after bariatric surgery BMC Obes 5 36-86

[8] Horowitz JM(2013)The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients Health Technol Assess 17 1-466

[9] Ishaaya E(2019)Risk of venous and arterial thrombosis in non-surgical patients receiving systemic tranexamic acid: A systematic review and meta-analysis Thromb Res 179 81-309

[10] Tapson VF(1989)Massive pulmonary thromboembolism after tranexamic acid antifibrinolytic therapy Br J Clin Pract 43 465-107

[1] Bĕlohlávek J(2013)Pulmonary embolism, part I: epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism Exp Clin Cardiol 18 129-138

[2] Dytrych V(2018)Epidemiology, pathophysiology, and natural history of pulmonary embolism Semin Intervent Radiol 35 92-98

[3] Linhart A(2020)Advances in the diagnosis of acute pulmonary embolism F1000Res 9 F1000 Faculty Rev-44-316

[4] Turetz M(2017)Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis Wien Klin Wochenschr 129 303-37

[5] Sideris AT(2015)Uses of tranexamic acid Cont Educ Anaesth Crit Care Pain 15 32-97

[6] Friedman OA(2009)The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database BJOG 116 91-79

[7] Triphathi N(2018)Tranexamic acid therapy for postoperative bleeding after bariatric surgery BMC Obes 5 36-86

[8] Horowitz JM(2013)The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients Health Technol Assess 17 1-466

[9] Ishaaya E(2019)Risk of venous and arterial thrombosis in non-surgical patients receiving systemic tranexamic acid: A systematic review and meta-analysis Thromb Res 179 81-309

[10] Tapson VF(1989)Massive pulmonary thromboembolism after tranexamic acid antifibrinolytic therapy Br J Clin Pract 43 465-107